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Background: Highly sensitized (HS) patients seldom have
chance to receive kidney transplant. To increase transplantation
rate among those population, previous IV immunoglobulin and
rituximab desensitization protocol showed good transplant con-
version rate, but also carried moderate rate of antibody mediated
rejection. Bortezomib, a proteasome inhibitor can control the
production of anti-HLA antibodies through plasma cell apoptosis.
A single center waitlist desensitization programwas employed to
facilitate successful kidney transplantation in HS patients group.
Methods: We prospectively enrolled 23 patients from Jul 2010
to Dec 2013. Desensitization protocol included two doses of IVIG
(2 g/kg), single dose of rituximab (375 mg/m2, max 500 mg), and
4 days of bortezomib (1.3 mg/m2 on days 1,3,7 and 9). Anti-HLA
class I and II antibodies were determined by Luminex solid phase
bead assay at baseline and M2, M3 and M6. We investigated the
difference of transplant conversion rate between desensitized HS
patients and non-desensitized HS waitlist patients. Also we
analyzed the difference of PRA % values and mean ﬂuorescence
intensity (MFI) between pre- and post-desensitization serum.
Results: Mean age of treatment group was 48.7711.2 years old.
Male to female ratio was 12:11. Oþ blood type patients were
34.8% of patients. Mean duration of previous renal replacement
therapy were 153.5765.5 months. Baseline mean class I and II
PRA % values were 86715.3 and 66734. Baseline class I and II
MFI values were 13,89376,147 and 12,27476,891. After desen-
sitization, kidney transplant were successfully performed in
34.8% of patients, compared to 13.8% transplant conversion rate
among non-desentized HS controls (p¼0.001 by Log-Rank).
Among KT recipients, median duration of waiting after desensi-
tization was 3 months with interquartile range 2-8.1 months.
Class I PRA % had showed decreased values until 3 months after
desensitization. After 6 months, there were no differences
between the class I PRA values between pre-desensitization
samples and post-desensitization samples. There were no other
differences except class I PRA % values. Desensitization protocolwere generally well tolerated, with the completion rate of 92%
patients. There were no serious adverse events, but moderate
adverse event were in 46%, most commonly fever and diarrhea.
Conclusion: Highly sensitized waitlist patients are manageable
by desensitization protocol including bortezomib.
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Background: While combination therapy of Rituximab (RTX)
and intravenous immunoglobulin (IVIg) (RIT) has been proposed
as therapeutic strategy for the treatment of chronic active
antibody-mediated rejection (CAMR), its efﬁcacy has not been
established. In this study, we compared clinical outcome
between the treatment group and historic control group to
ascertain the efﬁcacy of combination therapy for CAMR.
Methods: Fifty-four patients diagnosed as CAMR from 2003 to
2013 were included in this study, among whom twenty-ﬁve
were treated with RTX (375 mg/m2) and IVIg (0.4 g/kg) for 4 days
(RIT group) and the remaining twenty-nine patients were
regarded as historic control group. We assessed the change of
allograft function before and after the diagnosis of CAMR in
terms of the amount of decline in estimated glomerular ﬁltration
rate per month (ΔeGFR) and also investigated allograft survival
rate after diagnosis of CAMR.
Results: Neither of the two groups showed any signiﬁcant differ-
ences with respect to clinical, historical and baseline characteristics
including age at biopsy and gender. Nor did they show any
remarkable differences on ΔeGFR and eGFR prior to and at the time
of biopsy. However, ΔeGFR improved signiﬁcantly to 0.027
1.3 mLdmin-1d1.73m-2 per month 6 months after biopsy compared
to that observed 6months before RIT (1.3371.21, po0.05). Hence,Δ
eGFR post-Bx was signiﬁcantly lower in treatment group compared
to that of historic control group. Moreover allograft survival rate after
biopsy was signiﬁcantly higher in treatment group at 3 years from
the diagnosis of CAMR.
